Which statement about solitary pulmonary nodules and management is accurate?

Which statement about solitary pulmonary nodules and management is accurate?

• A. Size thresholds guide follow-up or biopsy; small nodules often no immediate workup; larger nodules require more aggressive evaluation.
• B. Size is irrelevant; always biopsy.
• C. All nodules require surgery.
• D. Nodules larger than 4 cm require no follow-up.

Answer: (C)

Understanding how size guides management of solitary pulmonary nodules is key. In practice, the size of a nodule is the first factor used to gauge cancer risk and decide what to do next. Small nodules are often followed with serial CT scans and may not need immediate invasive testing, especially in patients with lower risk. When a nodule is larger or if clinical risk is higher, clinicians move toward more definitive evaluation, which can include PET-CT to assess metabolic activity, needle or bronchoscopic biopsy, or even surgical resection if cancer cannot be ruled out. This approach balances avoiding unnecessary procedures in likely benign lesions with promptly diagnosing lesions that could be malignant. So the statement that size thresholds guide follow-up or biopsy, with small nodules often not requiring immediate workup and larger nodules prompting more aggressive evaluation, reflects how management is actually approached. The other ideas — that size doesn’t matter and every nodule should be biopsied, that all nodules need surgery, or that nodules above a certain size require no follow-up — don’t fit clinical practice because they ignore the nuanced risk-based decision making driven by size, morphology, and patient factors.

Understanding how size guides management of solitary pulmonary nodules is key. In practice, the size of a nodule is the first factor used to gauge cancer risk and decide what to do next. Small nodules are often followed with serial CT scans and may not need immediate invasive testing, especially in patients with lower risk. When a nodule is larger or if clinical risk is higher, clinicians move toward more definitive evaluation, which can include PET-CT to assess metabolic activity, needle or bronchoscopic biopsy, or even surgical resection if cancer cannot be ruled out. This approach balances avoiding unnecessary procedures in likely benign lesions with promptly diagnosing lesions that could be malignant.

So the statement that size thresholds guide follow-up or biopsy, with small nodules often not requiring immediate workup and larger nodules prompting more aggressive evaluation, reflects how management is actually approached. The other ideas — that size doesn’t matter and every nodule should be biopsied, that all nodules need surgery, or that nodules above a certain size require no follow-up — don’t fit clinical practice because they ignore the nuanced risk-based decision making driven by size, morphology, and patient factors.